Publications en collaboration avec des chercheurs de Instituto de Investigación Sanitaria de Navarra (24)

2024

  1. Exploring current and emerging therapies for porphyrias

    Liver International, Vol. 44, Núm. 9, pp. 2174-2190

  2. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

  3. Porphyrins and the porphyrias

    Liver International

  4. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  5. The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders

    Cellular and Molecular Gastroenterology and Hepatology

2023

  1. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  2. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2022

  1. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3815-3830

  2. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 55-96

  3. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

    Life, Vol. 12, Núm. 11

2021

  1. Acute intermittent porphyria, givosiran, and homocysteine

    Journal of Inherited Metabolic Disease

  2. Diagnosis and management of inborn errors of metabolism in adult patients in the emergency department

    Diagnostics, Vol. 11, Núm. 11

  3. Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection

    Biomedicine and Pharmacotherapy, Vol. 137

  4. High prevalence of insulin resistance in asymptomatic patients with acute intermittent porphyria and liver-targeted insulin as a novel therapeutic approach

    Biomedicines, Vol. 9, Núm. 3, pp. 1-18

  5. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

2019

  1. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model

    Molecular Genetics and Metabolism, Vol. 128, Núm. 3, pp. 367-375

  2. Messenger RNA therapy for rare genetic metabolic diseases

    Gut, Vol. 68, Núm. 7, pp. 1323-1330

2018

  1. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

    Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909

2016

  1. Emerging therapies for acute intermittent porphyria

    Expert Reviews in Molecular Medicine, Vol. 18